

BRISTOL MYERS SQUIBB CO  
Form 8-K  
November 09, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2006

---

**BRISTOL-MYERS SQUIBB COMPANY**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**1-1136**  
(Commission File Number)

**22-079-0350**  
(IRS Employer

Identification Number)

**345 Park Avenue**

**New York, NY, 10154**

(Address of Principal Executive Office)

Registrant's telephone number, including area code: **(212) 546-4000**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Edgar Filing: BRISTOL MYERS SQUIBB CO - Form 8-K

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On November 9, 2006, Bristol-Myers Squibb Company (the Company ) issued a press release announcing that it has commenced a cash tender offer to purchase any and all of its outstanding \$2.5 billion aggregate principal amount 5.75% Notes due 2011 (the Notes ). The Company also announced its intention to give a notice of redemption, with respect to any Notes that remain outstanding following consummation of the tender offer, subject to the receipt of net proceeds of the issuance of new debt securities.

A copy of the press release is filed as Exhibit 99.1 to this report.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 Press release of Bristol-Myers Squibb Company dated November 9, 2006

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRISTOL-MYERS SQUIBB COMPANY

Dated: November 9, 2006

By: /s/ Sandra Leung  
Name: Sandra Leung  
Title: Secretary

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release of Bristol-Myers Squibb Company dated November 9, 2006